Cargando…

165. Comparative Effectiveness of Oral Fluoroquinolones vs. β-Lactams for the Treatment of Patients with Enterobacteriaceae Bloodstream Infections

BACKGROUND: Fluoroquinolones (FQ) are associated with unacceptable rates of adverse drug events (ADE) and drug resistance. Safe and effective alternative oral agents are needed for definitive treatment of Enterobacteriaceae bloodstream infections (BSI). This study aims to determine whether treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bjork, Lauren, Hopkins, Teri, Yang, Linda, Frei, Christopher R, Jones, Xavier, Cadena, Jose, Walter, Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808865/ http://dx.doi.org/10.1093/ofid/ofz360.240

Ejemplares similares

Comparative-Effectiveness of Oral Beta-Lactams and Fluoroquinolones for Stepdown Therapy in Patients with Enterobacterales Bloodstream Infections: A Retrospective Cohort Study
por: Bjork, Lauren, et al.
Publicado: (2023)

1072. Streamlining to Oral β-Lactam vs. Fluoroquinolone as Definitive Therapy for Enterobacteriaceae Bacteremia
por: Fong, Karen, et al.
Publicado: (2018)

Oral Fluoroquinolone or Trimethoprim-Sulfamethoxazole vs ß-Lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis
por: Punjabi, Chitra, et al.
Publicado: (2019)

1040. Comparative Characteristics of Patients With Pseudomonas Bacteremia Receiving Intravenous Only vs. Intravenous Followed by Oral Therapy
por: Vu, Trung, et al.
Publicado: (2018)

210. Step-down from IV to oral therapy in patients with bacteremia due to Enterobacteriaceae: fluoroquinolones (FQ) vs. ß-lactams (BL) or trimethoprim-sulfamethoxazole (TMP-SMX)
por: Meng, Lina, et al.
Publicado: (2019)

Fluoroquinolone Versus Nonfluoroquinolone Treatment of Bloodstream Infections Caused by Chromosomally Mediated AmpC-Producing Enterobacteriaceae
por: Gunter, Sarah Grace, et al.
Publicado: (2020)

Oral β-Lactam Antibiotics vs Fluoroquinolones or Trimethoprim-Sulfamethoxazole for Definitive Treatment of Enterobacterales Bacteremia From a Urine Source
por: Sutton, Jesse D., et al.
Publicado: (2020)

308. Re-purposing Beta-lactam Antibiotics as Fluoroquinolone Sparing Stepdown Therapy for the Treatment of Enterobacteriales Bloodstream Infections
por: Davis, Matthew, et al.
Publicado: (2020)

1795. Safety Outcomes of the Use of β-Lactam Therapy in Patients With Documented β-Lactam Allergy
por: Bjork, Lauren
Publicado: (2018)

β-Lactam Resistance and Enterobacteriaceae, United States
por: Whichard, Jean M., et al.
Publicado: (2005)

271. Clinical Outcomes Treating Gram-Negative Bacteremia with Oral Beta-Lactams vs. Trimethoprim-Sulfamethoxazole or Fluoroquinolone Step-Down Therapy
por: Sinclair, Emily, et al.
Publicado: (2020)

216. Step-down Therapy With Oral Fluoroquinolones vs. Oral β-Lactams for Hospitalized Adult Patients with Community-Acquired Pneumonia: A Multi-Hospital Cohort Study
por: Petty, Lindsay, et al.
Publicado: (2018)

Beta-Lactam vs. Fluoroquinolone Monotherapy for Pseudomonas aeruginosa Infection: A Systematic Review and Meta-Analysis
por: Reid, Eric, et al.
Publicado: (2021)

Antimicrobial resistance in Enterobacteriaceae in Brazil: focus on β-lactams and polymyxins
por: Sampaio, Jorge Luiz Mello, et al.
Publicado: (2016)

284. Evaluation of Oral Step-Down Therapy for Enterobacteriaceae Bloodstream Infection
por: Utley, Sara, et al.
Publicado: (2020)

129. Beta-lactam vs Fluoroquinolone Monotherapy for pseudomonas Aeruginosa infection: A Systematic Review and Meta-analysis
por: Reid, Eric C, et al.
Publicado: (2020)

Respiratory Fluoroquinolones Monotherapy vs. β-Lactams With or Without Macrolides for Hospitalized Community-Acquired Pneumonia Patients: A Meta-Analysis
por: Liu, Sitong, et al.
Publicado: (2019)

Molecular Mechanisms, Epidemiology, and Clinical Importance of β-Lactam Resistance in Enterobacteriaceae
por: De Angelis, Giulia, et al.
Publicado: (2020)

277. Comparison of Oral Beta-Lactams and Fluoroquinolones for Step-Down in Uncomplicated Enterobacterales Blood Stream Infections
por: Ngo, Nichol, et al.
Publicado: (2020)

Prevalence of Beta-Lactam and Quinolone/Fluoroquinolone Resistance in Enterobacteriaceae From Dogs in France and Spain—Characterization of ESBL/pAmpC Isolates, Genes, and Conjugative Plasmids
por: Dupouy, Véronique, et al.
Publicado: (2019)

Hospital-acquired enterobacteriaceae Bloodstream Infections in Children
por: Kłos, Marta, et al.
Publicado: (2019)

254. Review of Clinical Outcomes in Patients Treated with Beta-lactam vs Non-beta-lactam Therapy for AmpC Producing Bacterial Bloodstream Infections
por: Staicu, Mary L, et al.
Publicado: (2020)

Effect of the Short-Term Use of Fluoroquinolone and β-Lactam Antibiotics on Mouse Gut Microbiota
por: Gu, Si-Lan, et al.
Publicado: (2020)

A Review of the Resistance Mechanisms for β-Lactams, Macrolides and Fluoroquinolones among Streptococcus pneumoniae
por: Zahari, Nurul Izzaty Najwa, et al.
Publicado: (2023)

Clinical utility of methicillin-resistant Staphylococcus aureus nasal PCR to streamline antimicrobial use in treatment of diabetic foot infection with or without osteomyelitis
por: Harb, Gaielle, et al.
Publicado: (2023)

2821. A Comparison of Empirical Therapy with Cefazolin Versus Ceftriaxone for the Treatment of Complicated Urinary Tract Infections in a Tertiary Care VA Medical Center
por: Carcamo, Paola, et al.
Publicado: (2023)

Characterization of fluoroquinolone resistance and qnr diversity in Enterobacteriaceae from municipal biosolids
por: Kaplan, Ella, et al.
Publicado: (2013)

Comparison Between Carbapenems and β-Lactam/β-Lactamase Inhibitors in the Treatment for Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: A Systematic Review and Meta-Analysis
por: Muhammed, Maged, et al.
Publicado: (2017)

1822. Clinical Outcomes Associated with Oral Beta-Lactam Therapy versus Oral Fluoroquinolones/TMP-SMX for Uncomplicated Gram-Negative Bacteremia
por: Kaur, Satwinder S, et al.
Publicado: (2022)

166. Comparison of Oral Fluoroquinolones to Alternative Oral Agents for Definitive Step-Down Therapy in Gram-Negative Bloodstream Infections
por: Cho, Christian Y, et al.
Publicado: (2019)

Impact of Multidrug-resistant Enterobacteriaceae Bloodstream Infections in Children
por: Aizawa, Yuta, et al.
Publicado: (2017)

Susceptibility to β-lactams and quinolones of Enterobacteriaceae isolated from urinary tract infections in outpatients
por: Marchisio, Martín, et al.
Publicado: (2015)

Genomic and phenotypic characterisation of fluoroquinolone resistance mechanisms in Enterobacteriaceae in Durban, South Africa
por: Osei Sekyere, John, et al.
Publicado: (2017)

Evaluation of automated systems for aminoglycosides and fluoroquinolones susceptibility testing for Carbapenem-resistant Enterobacteriaceae
por: Zhao, Zhichang, et al.
Publicado: (2017)

1549. Impact of New Fluoroquinolone Breakpoints on Enterobacteriaceae Susceptibility Rates and Clinical Outcomes
por: Pettit, Natasha N, et al.
Publicado: (2019)

The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia
por: Mortensen, Eric M, et al.
Publicado: (2006)

Effects of β-Lactam Antibiotics and Fluoroquinolones on Human Gut Microbiota in Relation to Clostridium difficile Associated Diarrhea
por: Knecht, Henrik, et al.
Publicado: (2014)

Enhancing activity of β-lactam and fluoroquinolones antibiotics by artemisinin and its derivatives against MDR Escherichia coli
por: Ul Haq, Shahbaz, et al.
Publicado: (2022)

Linear Regression Equations To Predict β-Lactam, Macrolide, Lincosamide, and Fluoroquinolone MICs from Molecular Antimicrobial Resistance Determinants in Streptococcus pneumoniae
por: Demczuk, Walter, et al.
Publicado: (2022)

1459. Oral Cephalosporins vs. Fluoroquinolones for the Empiric Treatment of Acute Uncomplicated Pyelonephritis
por: Lin, Kevin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_l8f0n9mekrfpupk5up70eirgqi